Patient Copay, Coverage, and Savings | Trudhesa® (dihydroergotamine mesylate) nasal spray | Healthcare Professional (HCP) Site

For the acute treatment of migraine in adults.

Important Safety Information

Prescribing Information

Patients can get Trudhesa^® for as little as $0 for their first fill.*

Commercially insured eligible patients will be enrolled in the Trudhesa Direct™ Savings Program and will receive Trudhesa for as little as $0 for their first fill.

Coverage for those with limited or no insurance.

If your patient is facing financial hardship or has limited or no insurance coverage, they can apply for the Impel Pharmaceuticals Patient Assistance Program. Simply have them call 1-800-589-0841 to sign up for this program.

*Terms and Conditions: All eligible, commercially insured patients pay as little as $0 for Trudhesa® (dihydroergotamine mesylate). If Trudhesa is not covered by the patient’s commercial insurance plan, the patient pays as little as $0 for the first box (4 Pods) and as little as $0 for each additional box up to four (4) boxes per calendar year.

Restrictions: This offer is valid in the United States only. Offer is available if a patient has a prescription, is commercially insured and is 18 years or older. Offer is not valid for patients who use any state or federal government-funded healthcare program to cover a portion of medication costs, such as Medicare (including Medicare Part D), Medicaid, Medigap, TRICARE, Department of Defense (DOD), Veterans Administration (VA), patients who are cash-paying or where prohibited by law. By using this offer, the patient certifies that he or she will comply with any terms of his or her insurance plan. It is illegal to (or offer to) sell, purchase, or trade this offer. Void where prohibited by law. This program does not constitute health insurance. The parties reserve the right to rescind, revoke or amend this offer without notice at any time.

References: 1. Impel NeuroPharma announces U.S. Food & Drug administration acceptance of new drug application for INP104 for the acute treatment of migraine [press release]. Impel Pharmaceuticals; January 20, 2021. https://impelnp.com/2021/01/20/impel-neuropharma-announces-u-s-food-drug-administration-acceptance-of-new-drug-application-for-inp104-for-the-acute-treatment-of-migraine/. Accessed September 10, 2021. 2. Randle L, Aurora SK, Hocevar-Trnka J, et al. Reduced nausea when dihydroergotamine mesylate is delivered by INP104. Poster presented at: American Headache Society Virtual Annual Scientific Meeting, June 3-6, 2021. 3. Craig K, Jeleva M, Hocevar-Trnka J. Cardiovascular safety results of INP104 (POD-DHE) from the STOP 301 phase 3 study. Poster presented at: American Headache Society Virtual Annual Scientific Meeting, June 3-6, 2021. 4. Trudhesa. Prescribing information. Impel Pharmaceuticals; 2021. 5. Smith TR, Winner P, Aurora SK, Jeleva M, Hocevar-Trnka J, Shrewsbury SB. STOP 301: a phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD®) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients. Headache. 2021;61(8):1214-1226.